Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 11 10; 34(32):3921-3930.

View in: PubMed

subject areas

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Multiple Myeloma
Oligopeptides
Quality of Life
Recurrence
Thalidomide
Young Adult

authors with profiles

Andrzej Jakubowiak